Education
About Us
Working with TipRanks
Follow Us
Incannex Healthcare Limited Sponsored ADR (IXHL)
NASDAQ:IXHL
IXHL Stock Chart & Stats
$0.39
-$0.11(-5.37%)
At close: 4:00 PM EST
$0.39
-$0.11(-5.37%)
Day’s Range― - ―
52-Week Range$2.40 - $49.80
Previous CloseN/A
Volume10.98K
Average Volume (3M)310.70K
Market Cap
$47.78M
Enterprise Value-$22.80M
Total Cash (Recent Filing)$68.90M
Total Debt (Recent Filing)$163.00K
Price to Earnings (P/E)―
Beta3.93
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding11,944,312
10 Day Avg. Volume530,610
30 Day Avg. Volume310,697
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.55
Price to Sales (P/S)86.40
P/FCF Ratio-0.59
Enterprise Value/Market Cap-0.48
Enterprise Value/Revenue-342.23
Enterprise Value/Gross Profit-342.23
Enterprise Value/Ebitda0.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
Regulatory Progress: FDA Fast Track & Phase 2 Success (IHL-42X)Fast Track designation plus positive Phase 2 RePOSA efficacy data materially de-risks the IHL-42X clinical program. This supports an accelerated regulatory pathway and strengthens the long-term commercial case for an oral OSA therapy addressing unmet patient needs, improving probability of approval and partner interest.
Strengthened Balance Sheet; Multi-year RunwayA sizable cash position and recent financing substantially reduce near-term solvency risk and give management flexibility to fund pivotal trials. Sustained runway into 2027 allows focus on data generation rather than immediate fundraising, improving chances of executing late-stage development without disruptive dilutive events.
Enhanced Clinical Governance Via Advisory BoardAdding renowned clinicians and researchers strengthens trial design, endpoint selection and regulatory strategy for PSX-001. Better scientific oversight reduces execution risk, increases the credibility of pivotal programs with regulators and partners, and can raise the likelihood of successful late-stage outcomes over the medium term.
Bears Say
Persistent Negative Operating And Free Cash FlowOngoing negative cash generation forces reliance on external capital to sustain operations and trials. Even with improved burn, persistent outflows create dilution risk and limit strategic optionality; sustained cash burn raises execution pressure to deliver clinical milestones that unlock non-dilutive funding or partnerships.
Heavy Net Losses; No Sustained Path To Profitability YetConsistent large losses mean the company is not yet converting R&D investment into commercial revenue or earnings. This results in negative returns on equity and forces prioritization of projects for value creation; absent clear commercialization, profitability remains a distant objective and investor returns hinge on successful approvals or partnerships.
Reverse Split To Regain Nasdaq ComplianceA reverse split reflects prior failure to meet listing price rules and signals structural liquidity and shareholder base challenges. Such corporate actions can reduce trading liquidity, complicate retail participation and indicate market perception issues that may increase the cost or difficulty of future equity raises over the medium term.
Incannex Healthcare Limited Sponsored ADR News
IXHL FAQ
What was Incannex Healthcare Limited Sponsored ADR’s price range in the past 12 months?
Incannex Healthcare Limited Sponsored ADR lowest stock price was $2.40 and its highest was $49.80 in the past 12 months.
What is Incannex Healthcare Limited Sponsored ADR’s market cap?
Incannex Healthcare Limited Sponsored ADR’s market cap is $47.78M.
When is Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date?
Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date is Sep 02, 2026 which is in 180 days.
How were Incannex Healthcare Limited Sponsored ADR’s earnings last quarter?
Incannex Healthcare Limited Sponsored ADR released its earnings results on Mar 02, 2026. The company reported -$0.6 earnings per share for the quarter, the consensus estimate of -$0.6 by $0.
Is Incannex Healthcare Limited Sponsored ADR overvalued?
According to Wall Street analysts Incannex Healthcare Limited Sponsored ADR’s price is currently Overvalued.
Does Incannex Healthcare Limited Sponsored ADR pay dividends?
Incannex Healthcare Limited Sponsored ADR does not currently pay dividends.
What is Incannex Healthcare Limited Sponsored ADR’s EPS estimate?
Incannex Healthcare Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Incannex Healthcare Limited Sponsored ADR have?
Incannex Healthcare Limited Sponsored ADR has 11,944,312 shares outstanding.
What happened to Incannex Healthcare Limited Sponsored ADR’s price movement after its last earnings report?
Incannex Healthcare Limited Sponsored ADR reported an EPS of -$0.6 in its last earnings report, expectations of -$0.6. Following the earnings report the stock price went down -9.906%.
Which hedge fund is a major shareholder of Incannex Healthcare Limited Sponsored ADR?
Currently, no hedge funds are holding shares in IXHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incannex Healthcare Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IXHL Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.66%
12-Months-Change
Fundamentals
Return on Equity
-130.42%
Trailing 12-Months
Asset Growth
575.36%
Trailing 12-Months
Company Description
Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Technical Analysis
Assertio Therapeutics
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
12.61% Insiders
0.03% Mutual Funds
0.22% Other Institutional Investors
86.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---